EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations

Christina S Thornton, Lindsay J Caverly, Linda M Kalikin, Lisa A Carmody, Scott McClellan, William LeBar, Don B Sanders, Natalie E West iD, Christopher H Goss, Patrick A Flume, Sonya L Heltshe, Donald R VanDevanter und 1 weitere

Annals of the American Thoracic Society · 2024

DOI: 10.1513/annalsats.202306-576oc ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of the American Thoracic Society, 2024. Verfasst von Christina S Thornton und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and. Hauptthemen laut MEDLINE: Cystic Fibrosis, Viruses, Respiratory Tract Infections, Virus Diseases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Rates of viral respiratory infection (VRI) are similar in people with cystic fibrosis (CF) and the general population; however, the associations between VRI and CF pulmonary exacerbations (PEx) require further elucidation.

Objectives

To determine VRI prevalence during CF PEx and evaluate associations between VRI, clinical presentation, and treatment response.

Methods

The STOP2 (Standardized Treatment of Pulmonary Exacerbations II) study was a multicenter randomized trial to evaluate different durations of intravenous antibiotic therapy for PEx. In this ancillary study, participant sputum samples from up to three study visits were tested for respiratory viruses using multiplex polymerase chain reactions. Baselines and treatment-associated changes in mean lung function (percent predicted forced expiratory volume in 1 s), respiratory symptoms (Chronic Respiratory Infection Symptom Score), weight, and C-reactive protein were compared as a function of virus detection. Odds of PEx retreatment within 30 days and future PEx hazard were modeled by logistic and Cox proportional hazards regression, respectively.

Results

A total of 1,254 sputum samples from 621 study participants were analyzed. One or more respiratory viruses were detected in sputum samples from 245 participants (39.5%). Virus-positive participants were more likely to be receiving CF transmembrane conductance regulator modulator therapy (45% vs. 34%) and/or chronic azithromycin therapy (54% vs. 44%) and more likely to have received treatment for nontuberculous Mycobacterium infection in the preceding 2 years (7% vs. 3%). At study visit 1, virus-positive participants were more symptomatic (mean Chronic Respiratory Infection Symptom Score, 53.8 vs. 51.1), had evidence of greater systemic inflammation (log10 C-reactive protein concentration, 1.32 log10 mg/L vs. 1.23 log10 mg/L), and had a greater drop in percent predicted forced expiratory volume in 1 second from the prior 6-month baseline (5.8 vs. 3.6). Virus positivity was associated with reduced risk of future PEx (hazard ratio, 0.82; 95% confidence interval, 0.69–0.99; P = 0.034) and longer median time to next PEx (255 d vs. 172 d; P = 0.021) compared with virus negativity.

Conclusions

More than one-third of STOP2 participants treated for a PEx had a positive test result for a respiratory virus with more symptomatic initial presentation compared with virus-negative participants, but favorable long-term outcomes. More refined phenotyping of PEx, taking VRIs into account, may aid in optimizing personalized management of PEx. Clinical trial registered with www.clinicaltrials.gov (NCT02781610).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisVirusesRespiratory Tract InfectionsVirus DiseasesHumansC-Reactive ProteinPrevalenceAnti-Bacterial Agents

Stichwörter der Autor:innen

cystic fibrosispulmonary exacerbationviral respiratory infection

Substanzen

C-Reactive ProteinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pediatrics and.
  • Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan.
  • Department of Pediatrics, Indiana University, Indianapolis, Indiana.
  • Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Department of Medicine and.
  • Department of Pediatrics, University of Washington, Seattle, Washington.

ORCID-Profile: Natalie E West

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • NIH HHS
  • Cystic Fibrosis Foundation
  • National Center for Advancing Translational Sciences
  • National Institutes of Health
  • BioFire Diagnostics

Zitieren

APA

Thornton, C. S., Caverly, L. J., Kalikin, L. M., Carmody, L. A., McClellan, S., LeBar, W., Sanders, D. B., West, N. E., Goss, C. H., Flume, P. A., Heltshe, S. L., VanDevanter, D. R., & LiPuma, J. J. (2024). Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations. Annals of the American Thoracic Society. https://doi.org/10.1513/annalsats.202306-576oc

Vancouver

Thornton CS, Caverly LJ, Kalikin LM, Carmody LA, McClellan S, LeBar W, et al. Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations. Annals of the American Thoracic Society. 2024. doi:10.1513/annalsats.202306-576oc

BibTeX
@article{Thornton2024,
  author = {Thornton, Christina S and Caverly, Lindsay J and Kalikin, Linda M and Carmody, Lisa A and McClellan, Scott and LeBar, William and Sanders, Don B and West, Natalie E and Goss, Christopher H and Flume, Patrick A and Heltshe, Sonya L and VanDevanter, Donald R and LiPuma, John J},
  title = {Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations},
  journal = {Annals of the American Thoracic Society},
  year = {2024},
  doi = {10.1513/annalsats.202306-576oc}
}
Kostenlos starten →